Table 1.
Infection rates of biologic injections per FDA package inserts
| Biologic | Upper respiratory tract infection for placebo, % (n) | Upper respiratory tract infection for drug, % (n) | Raw difference, % | |
|---|---|---|---|---|
| TNF-α | Infliximab (Remicade) | 14*x (41) | 15*x (135) | +1 |
| Etanercept (Enbrel) | 13* (25) | 13* (51) | 0 | |
| Adalimumab (Humira) | 4 (14) | 7 (59) | +3 | |
| Certolizumab (Cimzia) | 5*x (5) | 7*x (24) | +2 | |
| IL-12/23 | Ustekinumab (Stelara) | 5*x (30) | 5*x (64) | 0 |
| IL-17 | Secukinumab (Cosentyx) | 1*x (3) | 3*x (36) | +2 |
| Ixekizumab (Taltz) | 3*x (12) | 3*x (51) | 0 | |
| Brodalumab (Siliq) | 6 (40) | 5 (112) | −1 | |
| IL-23 | Tildrakizumab (Ilumya) | 3*x (9) | 2*x (25) | −1 |
| Guselkumab (Tremfya) | 5* (19) | 5* (41) | 0 | |
| Risankizumab (Skyrizi) | 2 (4) | 5 (28) | +3 |
IL, interleukin; TNF, tumor necrosis factor.
* Data collected from pivotal phase III trials reported as mean. *x Combined doses reported as mean.